In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
David Williamson, Motley Fool health care analyst, thinks Isis should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Joel South, energy analyst at The Motley Fool, thinks Energy Transfer Partners is a great investment for dividend lovers. The Master Limited Partnership currently distributes a very respectable 6.6% yield, but with strong segment diversification, a proven track record of executing on project backlogs and a built out pipeline infrastructure ready to service U.S. LNG exports, distributable cash flows should continue to pick up for unitholders.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson has no position in any stocks mentioned. Joel South has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.